stockrow
Monday 9 November 2026
Export IXHL’s income statement to Excel — free account
Incannex Healthcare Inc.
IXHLHealthcare Drug Manufacturers Specialty & Generic
Incannex Healthcare Inc.’s revenue for fiscal 2025 (year ended June 2025) was $86,000.00, up 616.7% from fiscal 2024.
- Revenue
- −92.3%
- EPS
- +98.6%
- Free cash flow
- +327.7%
Quarter to June 2026, against a year earlier
2.24
0.03
−1.32%
Follow IXHL
Alert me
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Piotroski F-Score |
— | 3 | 3 | 5 | 6 | — | — | — | — | — |
P/S ratio |
— | 4.76 | 24.03 | 45,498.60 | 73,245.27 | 266,845.52 | 266,845.52 | — | 266,845.52 | 266,845.52 |
Altman Z-Score |
— | (13.23) | (9.27) | 11.64 | 299.63 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | (26.78) | (26.91) | (13.64) | 17.24 | (9.20) | (29.79) | — | (181.82) | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
P/Operating CF |
— | (5.01) | (13.08) | (35,161.88) | (15,631.51) | (136,031.98) | (136,031.98) | — | (136,031.98) | (136,031.98) |
Beneish M-Score |
— | (5.82) | 3,578.30 | (10.17) | (1.23) | — | — | — | — | — |
P/B ratio |
— | 0.55 | 4.25 | 4,332.55 | 5,581.53 | 37,504.72 | 37,504.72 | — | 37,504.72 | 37,504.72 |
Price to Tangible BV |
— | 0.55 | 4.25 | 0.00 | 5,581.53 | 37,576.93 | 37,576.93 | — | 37,576.93 | 37,576.93 |
EV/Sales |
— | (2.45) | 21.34 | 45,487.72 | 73,231.55 | 266,838.29 | 266,838.29 | — | 266,838.29 | 266,838.29 |
EV/EBITDA |
— | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Operating CF |
— | 0.31 | (2.67) | (4,504.56) | (7,880.69) | (49,150.21) | (49,150.21) | — | (49,150.21) | (49,150.21) |
EV/FCF |
— | 0.31 | (2.62) | (4,433.49) | (7,880.69) | (49,150.21) | (49,150.21) | — | (49,150.21) | (49,150.21) |
Quick Ratio |
48.45 | 2.75 | 2.79 | 8.75 | 18.80 | 12.31 | 3.75 | 0.22 | 0.28 | 0.79 |
Current Ratio |
48.81 | 2.86 | 2.88 | 9.02 | 18.84 | 12.36 | 3.95 | 0.41 | 0.49 | 1.09 |
Net Debt/EBITDA |
2.97 | 0.64 | 0.20 | 0.45 | 2.52 | 0.80 | 0.90 | 0.02 | (0.03) | 0.04 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12.55% | 49.44% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.16) | (0.91) | (2.35) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.29 | 0.31 | 0.00 | 2.86 | 0.34 |
Operating CF/Net income |
0.67 | 0.27 | 0.86 | 0.22 | 0.86 | 0.61 | 0.83 | 0.79 | 0.97 | 0.13 |
Capex/Depreciation |
(0.04) | (0.03) | (2.69) | (3.59) | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | (78.51) | — | (206.72) | (2,488.66) | (6,076.89) | (1,788.13) | 0.00 | (325.05) | (101.51) |
| (47.80%) | (381.09%) | (115.22%) | (208.38%) | (66.60%) | (198.54%) | (343.08%) | 660.44% | 1,055.51% | 7,693.35% | |
| (41.32%) | (250.09%) | (90.42%) | (190.43%) | (62.69%) | (172.48%) | (197.18%) | (428.85%) | (832.89%) | (2,460.51%) | |
ROIC |
0.00% | 0.00% | (350.36%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(27.06%) | (355.05%) | (166.99%) | (235.34%) | (41.55%) | (132.65%) | (148.45%) | 582.60% | 648.77% | (18,507.51%) |
Average Days of Receivables |
0.00 | 17,536.98 | 299,208.75 | 76.21 | 136.38 | 31.93 | 207.22 | 0.00 | 19.51 | 120.63 |
Research and Development Expense of Revenue |
0.00% | 12,496.51% | 107,325.00% | 4,494.61% | 681.11% | 245.68% | 0.00% | — | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 15,265.12% | 143,116.67% | 864.48% | 825.15% | 299.40% | 518.85% | 0.00% | 239.71% | 769.01% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.10 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 3,033.72% | 74,400.00% | 231.87% | 185.69% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Graham Net Nets |
— | 1.74 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Earnings Yield |
— | (557.26%) | (38.87%) | (3.08%) | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Free Cash Flow Yield |
— | (168.62%) | (33.84%) | (0.02%) | (0.01%) | 0.00% | 0.00% | — | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.07 | 0.02 | 1.81 | 0.36 | 0.01 | 0.00 | 0.00 | 0.06 | 0.03 |
Operating CF per Share |
(1.10) | (10.90) | (29.44) | (20.98) | (5.86) | (0.02) | (0.02) | (0.01) | (0.16) | (0.27) |
Capex per Share |
0.00 | (0.01) | (0.51) | (0.62) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.10) | (10.91) | (29.95) | (21.60) | (5.86) | (0.02) | (0.02) | (0.01) | (0.16) | (0.27) |
Cash per Share |
5.81 | 13.10 | 10.88 | 43.18 | 17.15 | 0.03 | 0.01 | 0.00 | 0.01 | 0.05 |
Shareholders Equity per Share |
5.78 | 11.66 | 20.84 | 40.65 | 16.40 | 0.03 | 0.01 | 0.00 | (0.02) | (0.02) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.78 | 11.66 | 20.84 | 40.65 | 16.40 | 0.03 | 0.01 | 0.00 | (0.02) | (0.02) |
Free Cash Flow |
(12.88) | (12.52) | (16.12) | (11.06) | (9.29) | (5.20) | (2.68) | (1.51) | (2.11) | (2.07) |
Working Capital |
71.34 | 12.98 | 10.58 | 20.45 | 26.02 | 6.45 | 2.17 | (0.39) | (0.41) | 0.05 |
Capital Expenditures |
(0.01) | (0.01) | (0.28) | (0.32) | — | — | — | (0.02) | (0.04) | (0.04) |
Net Current Asset Value |
67.22 | 12.90 | 10.37 | 20.04 | 26.02 | 6.45 | 2.17 | (0.39) | (0.41) | (0.25) |
EV/EBIT |
— | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.09 | 23.08 | 0.34 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
60.00 | 1.08 | 0.22 | 0.30 | — | — | 0.00 | 0.49 | 0.56 | 0.70 |
Cash ROIC |
(9.53%) | (44.04%) | (94.42%) | (25.77%) | (17.46%) | (39.04%) | (57.73%) | 834.45% | (1,276.76%) | (359.05%) |
Accounts Receivable Turnover |
0.00 | 0.01 | 0.00 | 4.55 | 3.36 | 7.09 | 2.74 | 0.00 | 13.42 | 3.88 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 7.29 | 2.00 | 0.09 | 3.59 | 2.31 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 5.74 | 0.22 | 7.86 | 5.06 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 115,736.74 | 30.29 | 221.11 | 3,276.29 | 100.15 | 160.30 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 68.65 | 1,331.07 | 45.14 | 74.10 |
Average Receivables |
4.36 | 6.98 | 5.02 | 0.20 | 0.17 | 0.21 | 0.18 | 0.06 | 0.06 | 0.06 |
Average Payables |
3.63 | 3.36 | 1.18 | 1.60 | 0.82 | 0.29 | 0.33 | 0.31 | 0.37 | 0.37 |
Average Inventory |
— | — | — | — | — | — | 0.12 | 0.14 | 0.17 | 0.17 |
Average Assets |
46.71 | 18.75 | 20.42 | 25.63 | 17.25 | 4.96 | 1.63 | 0.44 | 0.26 | 0.65 |
Average Common Equity |
40.38 | 12.30 | 16.02 | 23.42 | 16.23 | 4.31 | 0.94 | (0.29) | (0.21) | (0.21) |
Columns are period end dates · fundamentals updated 26 Oct 2026